Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48- kD DNA-binding protein, ISGF3-gamma by unknown
Interferon  (IFN)  13 Acts Downstream  of IFN-~/-induced 
Class II Transactivator Messenger RNA Accumulation 
to Block Major Histocompatibility  Complex Class II 
Gene Expression and Requires the 48-kD DNA-binding 
Protein, ISGF3-~ 
By Hong-Tao Lu,*:~  James L. Riley,w  Gerald T. Babcock,* 
Michael Huston,II George R. Stark,* Jeremy M. Boss,w 
and Richard M. Ransohoff*~: 
From the *Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195; ~.Department 
of Bioflogy, Cleveland State University, Cleveland, Ohio 44115; w  of Microbiology and 
Immunology, Emory University,  Atlanta, Georgia 30322; and IIDepartment of Immunology, Berlex 
Biosciences, Richmond, California 94804 
Summary 
Interferon (IFN) ",/, a cardinal proinflammatory cytokine, induces expression of the gene prod- 
ucts of the class II locus of the major histocompatibility complex (MHC), whereas IFN-0t or 
-[3 suppresses MHC class II expression. The mechanism of IFN-13-mediated MHC class II in- 
hibition has been unclear.  Recently, a novel factor termed class II transactivator (CIITA) has 
been identified as essential for IFN-~/-induced MHC class II transcription. We studied the sta- 
tus  of IFN-~/-induced  CIITA messenger P,  NA  (mI(NA)  accumulation  and  CIITA-driven 
transactivation in IFN-13-treated cells and used cell lines that had defined defects in the type I 
IFN response pathway to address the roles of IFN signaling components in the inhibition of 
MHC class II induction.  IFN-~ treatment did not suppress IFN-~-induced accumulation of 
CIITA mR~A. After cells were stably transfected with CIITA, endogenous MHC class II genes 
were constitutively expressed, and MHC class II promoters, delivered by transfection, were ac- 
tively transcribed in  CIITA-expressing cells.  Expression of these promoters was significantly 
impaired by pretreatment with IFN-[3. These results suggest that IFN-[3 acts downstream of 
CIITA mRNA  accumulation,  and  acts  in  part  by  reducing  the  functional  competence  of 
CIITA for transactivating MHC  class II promoters.  IFN stimulated gene factor 3  (ISGF3) 
was essential for IFN-[3 to mediate inhibition of MHC class II induction, regardless of whether 
MHC class II transcription was stimulated by IFN-~ or directly by CIITA expression. Results 
of these experiments suggest that inhibition  of MHC class II in IFN-[3-treated cells  requires 
expression of gene(s)  directed by the  ISGF3-IFN-stimulated response element pathway, and 
that these gene product(s)  may act by blocking CIITA-driven transcription  of MHC  class II 
promoters. 
B 
iochemical and genetic studies of signaling by the IFNs 
recently culminated in a convincing and lucid descrip- 
tion of the process by which type I IFNs induce transcrip- 
tion of a set of immediate response genes, termed the IFN- 
responsive genes (ISGs)  1 (1). This pathway has been proposed 
1Abbreviations used in this paper: CAT, chloramphenicol acetyltransferase; 
CIITA, class II transactivator; EMSA, electrophoresis  mobility  shift assay; 
GAS, T-activated sequence; ISG, IFN-responsive gene; ISGF3, IFN- 
stimulated gene factor  3; ISRE, IFN-stimulated  response element; mRNA, 
messenger RNA; MS, multiple sclerosis; PTK, protein tyrosine kinase; 
STAT, signal transducer and activator  of transcription. 
as  a  paradigm for a  "direct  effector"  model  of transcrip- 
tional  regulation  by cytokines,  involving protein-protein 
interactions to form a transcriptional activator, IFN-stimu- 
lated gene factor 3  (ISGF3), which  can activate transcrip- 
tion  via  an  inducible  enhancer,  the  IFN-stimulated  re- 
sponse element (ISRE). Upon receptor binding by IFN-ot 
or IFN-~, latent  cytoplasmic transcription  factors,  collec- 
tively termed ISGF3-ot, were shown to be phosphorylated 
on  tyrosine  residues  and  to  accumulate  in  the  nucleus, 
where they formed a complex with a 48-kD DNA-binding 
protein, designated ISGF3-~/. These components were des- 
ignated ISGF3, which was shown to be essential to induce 
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taining ISILEs. 
Unexpectedly, this research revealed that type I (IFN-a 
or  IFN-[3)  and  type  II  (IFN-3')  IFNs,  despite  signaling 
through unique receptors, share certain transcriptional reg- 
ulatory components  (2).  In  particular,  a  91-kD  ISGF3-0~ 
component,  designated signal  transducer  and  activator of 
transcription  (STAT)  10~, and  a  nonreceptor protein  ty- 
rosine kinase (PTK) termed JAK1, proved to be absolutely 
required for response to both types I  and  II  IFNs  (2-4). 
Other components, such as the transcription factors ISGF3-',/ 
and p113/STAT-2, as well as the PTK tyk2, were impli- 
cated particularly in signaling by the type I IFNs. The PTK 
JAK2 was used specifically by IFN-~/(1, 5, 6). These results 
explained  previously  described  signaling  interactions  be- 
tween the partially overlapping pathways used by the two 
IFN types (7). 
The  ISGs  encode products  that  mediate  the  biological 
consequences of IFN treatment, including antiviral,  growth- 
regulatory, and immune-modulatory effects (8). Prominent 
among these effects,  IFN treatment regulates expression of 
MHC antigens (8). Either of the two IFN subtypes, type I 
or type II IFN, up-regulate expression of MHC class I anti- 
gens  (9).  It  has  been  shown  that  MHC  class II  antigens 
were  responsive to  IFN-%  whereas  IFN-ot and  -13 were 
typically unable to induce MHC class II expression (9). In 
fact, for many cell types, type I  IFN was shown to block 
the induction of  MHC class II expression by IFN-~/(10-12). 
These contrasting consequences oflFN-~/and IFN-[3 treat- 
ment for MHC class II expression might be ofpathogenetic 
significance, as IFN-~/and IFN-[~ recently exhibited highly 
divergent effects in regulating the human inflammatory de- 
myehnating disorder multiple  sclerosis  (MS).  MS  patients 
treated with IFN-~/experienced elevated disease activity, ac- 
companied by immune stimulation (13,  14). Patients treated 
with IFN-~ experienced fewer and milder attacks, with di- 
minished disease progression as monitored by magnetic-res- 
onance brain scanning (15,  16). IFN-[3 may ameliorate MS 
by down-regulating pathogenic MHC class II expression in 
the affected central nervous system tissues (17). 
In this regard, we and others have shown that IFN-[3- 
mediated blockade  of IFN-~/-induced  MHC  class II  ex- 
pression occurred at the transcriptional level (18,  19). Tran- 
scriptional  suppression  of MHC  class  II  by  IFN-[3  was 
relatively gene specific and did not require sequence con- 
tent, beyond the conserved MHC class II cis-regulatory  el- 
ements that were also required for response to IFN-',/(20). 
MHC class II expression has been intensely investigated 
in recent years (9, 21-24). Expression of MHC class II was 
shown to be regulated developmentally and environmen- 
tally,  in a remarkably specific and stringent fashion. Tran- 
scriptional  activity  of the  MHC  class II  genes  has  been 
shown  to determine their expression, and several lines of 
evidence have indicated selective transcriptional control of 
the MHC class II genes. The strongest support for this no- 
tion came from human patients with bare lymphocyte syn- 
drome, an autosomal-recessive deficiency of MHC class II 
gene  expression (25).  Further,  two  groups  generated cell 
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lines with selective defects in the IFN-y pathway for MHC 
class II expression (26, 27). MHC class II gene induction by 
IFN-y required intermediary protein synthesis in most cells 
(28, 29). Additionally, the regulatory cis element for MHC 
class II  transcription was  quite  different from the y-acti- 
vated  sequence  (GAS)  element  that  governed the  direct 
(protein  synthesis-independent)  response  to  IFN-~/  (1). 
Taken together, studies of IFN-~/induction of MHC class 
II transcription indicated an indirect mechanism requiring 
synthesis of a protein factor, in addition to the direct JAK- 
STAT pathway.  Class  II  transactivator  (CIITA),  a  novel 
transcription factor deficient in one bare lymphocyte syn- 
drome complementation group, has  recently been identi- 
fied by a variety of genetic and biochemical strategies  as the 
IFN-y-inducible factor that was necessary for MHC  class 
II transcription (30-33). 
Based on recent reports, ClITA is proposed to activate 
MHC class II transcription by interacting (directly or indi- 
rectly) with factors bound to regulatory DNA elements up- 
stream of the structural genes (34, 35).  Furthermore, CIITA 
contains a potent NH2-terminal transactivation domain that 
functions in heterologous context (34, 35). Taken in aggre- 
gate, these observations prompted the attractive hypothesis 
that  physical  interaction between  CIITA  and  promoter- 
bound components positions the transactivator domain to 
provide a stimulatory interface between the MHC class II 
gene-specific factors and the  basal  transcription  apparatus 
(34, 35). 
Experiments described in this report addressed the role 
of CIITA in the pathway by which IFN-[3 inhibited MHC 
class II expression. Additionally, cell lines with defined de- 
fects in type I IFN signaling were used to address the func- 
tions  of individual  ISR.E-ISGF3  signaling  components. 
Initial experiments were performed in the parental fibrosar- 
coma cell line 2fTGH, which responds to IFN-~ with ex- 
pression of MHC  class II antigens, and this induction can 
be  readily suppressed  by  IFN-[3.  As  anticipated,  CIITA 
messenger RNA (mRNA) accumulated in 2fTGH cells af- 
ter induction with IFN-~/. We found that IFN-13 treatment 
did not suppress  IFN-~-induced CIITA mRNA accumu- 
lation.  2fTGH  cells  that  were  stably  transfected  with  a 
CIITA expression construct displayed MHC  class II anti- 
gens in the absence oflFN-% and MHC class II promoter/ 
reporters  were  strongly  activated  in  CIITA-transfected 
ceils. IFN-[3 pretreatment impaired the expression of MHC 
class II promoter/reporter constructs in CIITA-transfected 
cells, and this inhibition was observed at modest concentra- 
tions of IFN-13.  Mutant cell lines were used to show that 
functional ISGF3-~/was required for IFN-[3 to mediate in- 
hibition  of MHC  class II  expression,  either  induced  by 
IFN-~/treatment or directly by CIITA expression. 
Taken together, these results  indicate that IFN-[3 treat- 
ment blocks MHC class II expression at a point subsequent 
to the accumulation of CIITA mRNA.  Our observations 
in cell lines with defined defects in IFN signaling suggest 
the hypothesis that an  IFN-[3-induced gene product,  ex- 
pressed  via  the  ISRE-ISGF3-dependent  pathway,  is  re- 
sponsible for the ability of IFN-[3 to down-regulate MHC 
Interferon 13 Acts Downstream of Class II Transactivator mRNA class II expression. Data reported here also demonstrate that 
IFN-[3 impairs the  expression of MHC  class II promoters 
in CIITA-transfected cells. We propose that this inhibitory 
effect  for  CIITA-driven  MHC  class  II  transcription  ac- 
counts at least in part for the ability of IFN-13 to abrogate 
1FN-~/-induced MHC  class II expression. 
Materials and Methods 
Cytokines.  Purified human  recombinant  IFN-3' (1.9  ￿  107 
U/rag protein) was generously provided by Genentech, Inc. (South 
San Francisco, CA). ILecombinant human IFN-[3 (108 U/rag pro- 
tein)  was  generously  provided  by  Biogen  (Cambridge,  MA). 
Wellferon, a purified mixture of IFN-ct subtypes (108 U/rag pro- 
tein), was kindly provided by Wellcome Research Laboratories 
(Kent, UK). 
Plasmids.  Construction ofpCIITA.2.11 and its use to direct 
expression of functional  CIITA have  been  described (31,  35). 
Construction of pDRA(267)CAT was previously described (20). 
This promoter-reporter construct contains 267 bp of 5'-flanking 
sequence of the human HLA-DRA gene and 27 bp of  transcribed 
sequence,  fused to  a  splice cassette,  and the bacterial chloram- 
phenicol acetyltransferase (CAT) gene. pGL2, an expression plas- 
mid containing a luciferase reporter gene under control of an SV40 
promoter, was obtained from Promega Corp. (Madison, WI). 
Cell Culture.  2fTGH and all derivative cell lines were grown 
in  complete  medium:  DME  with  10%  heat-inactivated  FCS 
(GIBCO/BRL, Gaithersburg, MD) and 250 Ixg/ml ofhygromy- 
cin B (Sigma Chemical Co., St. Louis, MO) (36). 
Mutant Cell Lines Defective in Response to IFN-ec/fl. The 2fTGH 
fibrosarcoma cell line and derivative mutants exhibiting defects in 
their response to IFN-cx were generated by lethal selection (37). 
Recessive mutant cell lines were organized into complementation 
groups, designated U  (unresponsive)-1 through U-6 (1, 37). Each 
complementation group contains one or more cell lines that are 
genetically defective for individual components of the IFN sig- 
naling pathway (1, 2,  36-38).  The parental cell line 2fTGH ex- 
hibits wild-type response to types I and II IFN (36).  U1A (ini- 
tially designated 11.1)  lacks tyk2 and is unresponsive to IFN-ot, 
but retains partial response to IFN-13 and full response to IFN-~/ 
(6,  36).  U2A lacks functional ISGF3-~ and is  unresponsive to 
IFN-ci and IFN-13 for gene expression directed by the ISRE, but 
retains full response to IFN-oe for an ISILE/ISGF3-independent 
pathway (1, 6, 36, 38, 39). U2A cells activate all IFN-~/-respon- 
sive genes tested (including the MHC class I and II antigens) ex- 
cept 1-8 and 9-27 (1, 38--40). 
Cell Lines Expressing CIITA 2.11.  For these studies, 2fTGH 
and derivative cell lines were cultured in 10-cm  2 dishes to "~70- 
80%  confluence and incubated with prewarmed complete me- 
dium containing pCIITA.2.11 and pSV2neo (41) plasmid DNAs 
(in  10:1  molar  ratio)  and  10  Ixg/rnl  hexadimethrine  bromide 
(Polybrene; Sigma Chemical Co.) for 6 h. Cells were washed once 
with PBS and shocked for 2 rain with 30% DMSO (Sigma Chem- 
ical Co.). The cells were incubated in 10 ml complete medium for 
2 d and subjected to selection in complete medium supplemented 
with 500 ~g/ml G418 (Sigma Chemical Co.) for 2-3 wk. 
Restoration of lSGF3- y Activity in U2A Cells.  U2A cells were 
transfected with pDRISGF3"? (kindly provided by Dr. Ganes Sen, 
Research Institute, Cleveland Clinic Foundation) and pSV2neo 
DNA in  10:1  molar ratio, subjected to selection for G418  (500 
~g/ml) resistance for 2 wk, and then selected for restoration of 
type I IFN response in DME containing IFN-oe (Wellferon, 500 
U/ml)  and  1￿  hypoxanthine-aminopterin-thymidine medium 
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(GIBCO  BRL)  for  1  wk,  incubated  without  aminopterin  in 
DME containing 1 ￿  hypoxanthine-thymidine medium (GIBCO 
BILL)  for 4  d,  and passaged routinely in  complete DME  (36). 
IFN-oe responsiveness was  confirmed by  demonstrating MHC 
class I induction. 
Northern Blot Hybridizations.  Northern blots were performed 
as described previously (19). A CIlTA cDNA fragment was gen- 
erated by PCR from a Daudi cell cDNA library kindly provided 
by Dr.  Taolin Yi  (Cleveland Clinic Foundation)  using primers 
that amplified residues 2909-3534 of the published sequence (42). 
The identity of the amplified segment was confirmed by sequence 
analysis,  after which a gel-isolated fragment was labeled by ran- 
dom priming for hybridization. 
Normalized  Transient Transfections.  Cells were cultured in 10- 
cm  2 dishes to "~70-80% confluence in the presence or absence of 
IFN-[3. Medium was replaced with 3 rnl ofprewarmed complete 
medium containing 10-20 ~g ofpDRA(267)CAT plasmid DNA, 
2-4  Ixg of pGL2 luciferase expression plasmid DNA  (Promega 
Corp.),  and  10  Ixg/ml Polybrene for  6  h,  and  the  cells  were 
washed once with PBS and shocked with 30% DMSO in 3 rnl of 
serum-free  media for  2  rain  at  room  temperature.  Cells were 
washed twice with incomplete medium and incubated for 48 h in 
complete medium before harvesting and normalized CAT assay. 
Cells were scraped in 1.4 ml PBS, pelleted for 2 rain in a mi- 
crocentrifuge, and  resuspended in  70  I.tl of 1￿  luciferase lysis 
buffer (Promega Corp.). Cell extracts were prepared by lysis with 
three cycles of freezing and thawing and clarified for 10 rain in a 
microcentrifuge. 10 btl of extract was subjected to luciferase assay 
according  to  the  manufacturer's  instructions.  Extract  input  to 
CAT assays was normalized to luciferase activity to  correct for 
transfection efficiency. 
Flow Cytometry,  Cells were immunostained for HLA-DIL and 
an isotype-matched control and analyzed on a FACscan  |  (Becton 
Dickinson &  Co.,  Mountain View,  CA) as described (12).  For 
each  data point,  the  percentage  of cells  staining with  isotype- 
matched control was subtracted from the experimental value, and 
results were  expressed as  the  percentage  of HLA-DR-positive 
cells. 
Because  of variability in  HLA-DIL induction,  data for these 
experiments were  not  normally distributed; however,  the  per- 
centages of inhibition by 1FN-o~ and IFN-~ were highly repro- 
ducible. Representative experiments are presented in the figures. 
Mean inhibitions of HLA-DIL induction in preliminary experi- 
ments were as follows: by IFN-oL in 2f'TGH cells, 71.3%  (n =  2); 
by IFN-13  in 2fTGH  cells,  94.2%  (n  =  6);  by IFN-ot in U1A 
cells,  20%  (n  =  2); by IFN-[3 in UIA cells, 48.8%  (n  =  2);  by 
IFN-0~ in U2A cells, 0%  (n  =  1); by IFN-13 in U2A cells, 5% 
(n =  3). 
Results 
IFN-'y-induced CIITA mRNA Accumulation Is Not Affected 
by IFN-~8.  It  has  recently  been  shown  that  CIITA  was 
necessary for  IFN-'y-induced MHC  class  II  transcription 
(30, 31, 33). This surprising result provided a unitary expla- 
nation for distinctive characteristics of IFN-'y regulation of 
MHC  class  II  expression,  including  the  requirement  for 
ongoing protein synthesis. 
We  considered the possibility that IFN-[3 might inhibit 
synthesis of CIITA as a plausible mechanism for suppress- 
ing MHC  class II expression. Northern blot hybridizations 
showed that CIITA mtLNA was induced in 2fTGH fibro- sarcoma cells by IFN-3,. CIITA mkNA  accumulation was 
unaffected by IFN-~ treatment at saturating concentrations 
that, in preliminary experiments, completely abrogated MHC 
class II expression (Fig. 1). This result indicated that the in- 
hibition of MHC  class II expression by IFN-~ was not me- 
diated by blocking CIITA mI~NA accumulation. 
IFN-~ Blocks Expression of MHC Class II Promoter~Report- 
ers in CIITA-expressing  Cells.  Expression of CIITA through 
DNA-mediated  gene  transfection  can  induce  MHC  class 
II transcription  in  the  absence  of  IFN-~/  (30,  31,  33). 
CIITA.2.11, an expression construct for CIITA that directs 
the  synthesis  of functional  protein,  was  stably transfected 
into  2fTGH  cells  (31).  Endogenous  MHC  class  II  genes 
were  induced  in  CIITA-expressing  2fTGH/CIITA.2.11 
cells,  as  monitored  by  flow  cytometry  (data  not  shown). 
This  MHC  class  II  expression was  dependent  on  expres- 
sion  of the  transfected  CIITA  gene,  as  transfection  with 
CIITA.10, which encodes a nonfunctional protein, did not 
produce MHC  class II expression (data not shown)  (35). 
In cells stably transfected with CIITA.2.11,  endogenous 
MHC  class  II  expression was  constitutive.  To  determine 
the  effect  of  IFN-~  treatment  on  constitutive  CIITA- 
driven MHC  class II expresson,  2fTGH/CIITA.2.11  cells 
were left untreated or exposed to IFN-~ (1,000 U/rnl) for 
48-72  h  and  were  assayed by  flow  cytometry for  MHC 
class  II  antigen.  Under  these  conditions,  IFN-~  did  not 
inhibit  CIITA-driven MHC  class  II  expression  (data  not 
shown). 
It  remained  possible  that  IFN-i3  treatment  blocked  an 
early  stage  of MHC  class  II  gene  expression  in  CIITA- 
transfected  cells,  and  that  FACscan  |  assay  of HLA-DP,, 
protein was insensitive to this effect. To address this point, 
CIITA-driven  expression  of MHC  class  II  promoter/re- 
porters was  assayed after normalized transient transfection. 
For these  experiments,  a  promoter-reporter construct  de- 
rived from the 5'-flanking region of the human MHC  class 
II HLA-DRA  gene, pDRA(267)CAT  was used (20).  This 
construct contains all sequence content required for the in- 
duction and inhibition of MHC  class II transcription. (20). 
Expression  of  this  MHC  class  II  reporter,  induced  by 
CIITA expression, was equivalent to that produced by opti- 
mal concentrations of IFN-~/. Activity of a  GAS-containing 
promoter-reporter construct,  pGBP.CAT,  was  unaffected 
by  CIITA  expression,  documenting  specificity for  MHC 
class II (data not shown). 
2fTGH/CIITA.2.11  cells were preincubated with IFN-~ 
or left untreated before transient transfection with pDRA- 
(267)CAT.  Pretreatment  with  IFN-i3  (125  U/ml)  caused 
significant  inhibition  of  MHC  class  II  transcription  in 
2fTGH/CIITA.2.11  cells (Fig.  2;  P  =  0.007  for medium 
vs.  125  U/ml  IFN-[5 by paired means  comparison).  Fur- 
ther,  we  observed a  significant inhibition in  cells exposed 
to  25  U/ml  IFN-~  (Fig. 2;  P  =  0.025  for medium vs.  25 
U/ml).  The magnitude and dose dependency of this inhi- 
bition were closely related to the IFN-13-mediated inhibi- 
tion  of  IFN-',/-induced  expression  of  the  endogenous 
HLA-DR  MHC  class II antigen. 
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Figure 1.  Northern  blot analysis of CIITA mR.NA in 2fTGH cells: 
regulation by IFN-~ and IFN-~. Cells were exposed for 6 h to IFN-'y 
(500 U/ml) alone or in combination with IFN-~ (1,000 U/ml) as indi- 
cated, before preparation of polyadenylated RNA and blot hybridization 
analysis. The filter was rehybridized with ~-actin probe (inset) to normal- 
ize for loading variation. Exposure to Phosphorlmager screen for CIITA: 
48 h; exposure for 13-actin: 30 min. 
Figure 2.  IFN-~ pretreatment impairs expression of MHC class  I1 pro- 
rooters in CIITA-expressing 2fTGH cells.  2fTGH cells  were stably trans- 
fected with CIITA.2.11 by cotransfection with a selectable marker (20). 
These  2fTGH/CIITA.2.11  cells were  exposed to  IFN-~ at  indicated 
concentrations overnight or left as untreated controls before washing and 
transient cotransfection with pDRA(267)CAT  (10 I.tg)  and pGL2 (5 ~g). 
2fTGH/CIITA.2.11  ceils were then incubated with or without  IFNs as 
indicated for 48 h before harvest. An aliquot of the cell lysate was sub- 
jected to luciferase  assay,  and luciferase  activity was used to correct extract 
inputs to CAT assays, to normalize for transfection efficiency. Each data 
point represents one assay;  two overlapping data points are present in the 
column  showing IFN-[~ treatment  at  125  U/ml.  Mean  percentage of 
chloramphenicol acetylation is  indicated.  IFN-13 pretreatment  signifi- 
cantly inhibited expression ofpDRA(267)CAT. 
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Figure  3.  ISGF3-"/ is  required  for IFN-[3 suppression of IFN-~- 
induced MHC class II expression. Cells were treated for 48 h with IFN-~/ 
(100 U/ml) alone or in the presence of IFN-I3 (1,000 U/ml) before im- 
munostaining with  mAb to HLA-DR or isotype-matched control and 
analysis by FACScan  | 
ISGF3- T Is Required for IFN-~-mediated  Inhibition of 
IFN-T-induced  MHC Class II Expression.  IFN-[3  treatment 
activates a signaling cascade that culminates in expression of 
gene products, which in turn mediate many of the biologi- 
cal effects attributed to IFN-[3. One possible mechanism by 
which  IFN-[3  could  inhibit  MHC  class  II  transcriptional 
induction was by activation of a preexisting signaling com- 
ponent  (e.g., protein kinase) in the IFN-[3 pathway. Alter- 
natively,  IFN-[3 could require  de novo gene expression to 
impair transcriptional induction of MHC  class II genes. 
It was possible to test the role of IFN-13-activated signal- 
ing components in the inhibition  of MHC  class II through 
the use of cell line U2A, which lacked functional  ISGF3-~ 
(1, 38). Despite the absence of functional ISGF3-~/in U2A 
cells,  IFN-a/~  signaling leading to the  generation  of acti- 
vated STAT-la/STAT-2  heterodimers  (ISGF3-a) has been 
documented  (1,  38).  Furthermore,  studies  in  U2A  cells 
showed that IFN-ot induces  expression of the  IRF-1  gene 
through  an alternative pathway that generates DNA-bind- 
ing  complexes  containing  STAT-la  (39).  These  results 
documented that U2A cells have intact IFN-a/[3-activated 
signaling components,  which  include  the  IFN-a/13  recep- 
tor complex, JAK1, tyk2, STAT-lcx, and STAT-2 (39). U2A 
was shown  in  these  studies  to be deficient  only in  ISRE- 
regulated gene expression. 
IFN-13  failed  to  inhibit  IFN-'y-induced  MHC  class  II 
antigen  expression  in mutant  U2A  cell line  (Fig.  3).  This 
result  suggests  that  ISGF3-~/  is required  for down-regula- 
tion of IFN-~/-induced MHC  class II expression; however, 
one possible trivial explanation  for this  observation would 
be a second site mutation in U2A cells. To address this is- 
sue,  we  restored  functional  ISGF3-~/  by  transfection  and 
back-selection, producing cell line U2A/p48, which was fully 
responsive to IFN-~.  In U2A/p48  cells, IFN-[3 suppressed 
MHC  class  II induction  equally  as  observed  in  the  wild- 
type  2fTGH  line,  demonstrating  formally  that  ISGF3-~/ 
was required for IFN-13 to inhibit MHC  class II expression 
(Fig. 4). These observations suggest that IFN-[3 acts through 
the ISGF3/ISRE-dependent  pathway to induce the expres- 
sion of gene(s)  whose product(s)  mediate the inhibition  of 
MHC  class II transcriptional  induction. 
To address further the role of gene expression in IFN-[3 
inhibition  of MHC  class  II, we performed studies  in  mu- 
tant cell line U1A, which was deleted for PTK tyk2, defec- 
tive in IFN-a binding to the receptor,  and completely un- 
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UIA cells retained a weak (~50%) gene regulatory response 
to IFN-[3 (36). IFN-[3 inhibited MHC class II induction in 
U1A cells  by 49%  (n  =  2)  vs.  94%  inhibition  in  2fTGH 
cells (n =  6; data not shown).  IFN-[3 caused a 45% reduc- 
tion of mean peak channel relative fluorescence intensity of 
HLA-DR.-positive U1A cells,  in addition  to reducing the 
number  of positive  cells.  This  observation  excluded  the 
possibility that  one subpopulation  of UIA  cells  responded 
with  wild-type competence to  IFN-[3, whereas  a  separate 
population  of cells  remained  entirely  refractory.  We  con- 
cluded  that  essentially  all  U1A cells  responded  weakly  to 
IFN-[3  for inhibition  of MHC  class  II induction.  As  ex- 
pected,  induction  of HLA-DR by IFN-~/ was resistant  to 
blockade in UIA  cells  by IFN-ot  (20% inhibition  vs.  71% 
inhibition in 2fTGH cells,  n  =  2; data not shown).  These 
results  indicate  that  PTK  tyk2  is  dispensable  for  IFN-13- 
mediated inhibition of MHC  class II induction and further 
support  a  correlation  between  ISGF3/ISRE-dependent 
gene expression and IFN-[3 inhibition of MHC class II. 
ISGF3-'y Is Required for IFN-[3-mediated Inhibition  of 
CIITA-induced MHC Class II Transcription.  Our results sug- 
gest that IFN-[3 inhibits  IFN-',/-induced MHC  class II ex- 
pression by impairing transcriptional induction from MHC 
class  II promoters, even in the presence of CIITA (Fig. 2). 
U2A cells  were used to study the role of IFN-t3-activated 
signaling components in inhibiting MHC class II induction 
Figure 5.  ISGF3-~  is required for IFN-[3 suppression of CIITA-driven 
MHC class II promoter/reporter expression. 2fTGH and U2A cells were 
stably transfected with  CIITA.2.11 by cotransfection with  a selectable 
marker (20). 2fTGH/CIITA.2.11  cells or U2A/CIITA.2.11  cells were 
exposed to IFN-[3 (500 U/ml) overnight or left as untreated controls be- 
fore washing and transient cotransfection  with pDR.A(267)CAT (10 ~g) 
and pGL2 (5 Izg). Cells were then incubated in complete medium with or 
without IFNs as indicated for 48 h before harvest. An aliquot of the cell 
lysate was subjected to luciferase assay, and luciferase activity was used to 
correct extract inputs to CAT assays to normalize for transfection effi- 
ciency. An autoradiogram  is shown; the percentage of  conversion of  CAT 
to acetylated product (% CAT) was determined by autoradiography  on a 
Phosphorlmager. The  percentage of inhibition of promoter activity by 
IFN-[3 (% INH) was determined as described in the legend to Fig. 4 and 
is indicated below. 
(Figs.  3 and 4). To address the role of these signaling com- 
ponents in suppressing CIITA-driven MHC class II expres- 
sion,  U2A  cells  that  stably  expressed  CIITA.2.11  were 
constructed.  Strikingly,  IFN-[3 failed to  inhibit  expression 
of pDRA(267)CAT  in U2A/CIITA.2.11  cells  in normal- 
ized  transient  transfections  (Fig.  5).  This  observation  fur- 
ther supports the conclusion that IFN-[3 induces expression 
ofgene(s), whose product(s) impairs IFN-~/-induced MHC 
class  II  expression,  acting downstream  of CIITA mlkNA 
accumulation. 
Discussion 
CIITA has  been  identified  as  a  novel  IFN-~/-inducible 
factor required  for MHC  class  II transcription,  providing 
new insight into the intricate regulation of these important 
gene products.  The  selective  function of CIITA for regu- 
lating MHC class II expression corresponded to the specific 
inhibition of MHC class II (among IFN-~/-inducible genes) 
by IFN-[3. This  relationship  prompted the hypothesis that 
IFN-[3 might suppress CIITA mlkNA accumulation or act 
downstream  of CIITA expression  to block its function  in 
mediating MHC  class  II induction.  In this  report,  we de- 
scribe studies of the effect of IFN-[3 on IFN-y induction of 
CIITA mR.NA;  we  further  characterize  IFN-[3  treatment 
effects  on the function of CIITA, afier expression by DNA- 
mediated  gene  transfer.  It was  found  that  IFN-13  did  not 
block the accumulation of the CIITA mRNA. This result 
was consistent with the status of CIITA as an immediate re- 
sponse  gene  for IFN-y  (33).  Among IFN-~/-induced  im- 
mediate response genes, only one (ICSBP) has been shown 
to  be  inhibited  by type  I  IFNs,  specifically in  macrophage 
cells  (43,  44).  Our  data  localize  the  inhibitory  effect  of 
IFN-~ for MHC  class  II expression subsequent to IFN-y- 
induced CIITA mP,  NA accumulation. 
We observed that IFN-[3 treatment significantly impaired 
expression of MHC class II promoters in CIITA-expressing 
cells in transient transfection experiments  (Fig. 2).  This re- 
sult  indicates  that CIITA protein  is  not fully functional in 
IFN-[3-treated cells.  The most straightforward explanation 
for this effect of IFN-[3 treatment would be that accumula- 
tion or competence of CIITA protein is modulated.  Poten- 
tial  mechanisms include  destabilization  or posttranslational 
modification  of the  CIITA protein,  abrogation  of CIITA 
interaction  with  MHC  class  II-specific  factors  associated 
with promoter elements,  or blockade of nuclear accumula- 
tion of CIITA. A  plausible  alternative  is that IFN-[3 treat- 
ment could result in modification or displacement of any of 
the  components  required  for MHC  class  II transcription, 
including  the  factors  (such  as  P,F-X,  X2BP,  NF-Y)  that 
contact DNA directly.  The interference  with these factors 
would then secondarily produce an apparent abrogation of 
CIITA function. 
In  other  systems,  IFN-mediated  transcriptional  inhibi- 
tion has shown varied characteristics. Vilcek and colleagues 
showed  that  the  IFN-mediated  inhibition  of  TNF-ix- 
induced IL-8 did not require protein synthesis, and the ef- 
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signaling components to address whether gene expression 
was  required  for  the  inhibition  of  IFN-~/-induced  and 
CIITA-driven MHC class II transcription. The most infor- 
mative mutant was U2A,  a  cell line lacking ISGF3-~/but 
otherwise competent for IFN signaling. IFN-[~ failed to in- 
hibit  MHC  class  II  transcription  in  U2A  cells,  whether 
stimulated by CIITA or by IFN-% Restoration oflSGF3-~ 
by transfection and back-selection for IFN response also re- 
paired the ability of IFN-[3 to block MHC class II expres- 
sion. This experiment confirmed that a fortuitous second mu- 
tation did not determine the U2A phenotype of resistance 
to MHC class II inhibition.  IFN-13 mediated a partial inhi- 
bition of HLA-DR induction in UIA cells. In experiments 
reported  previously,  ISG  expression  was  stimulated  by 
IFN-[3 in UIA cells with ,',~50% of  wild-type efficiency (36). 
The observations described in this report establish a close 
relationship between IFN-[3-inducible gene expression via 
the ISGF3-ISRE pathway and inhibition of MHC class II 
expression. IFN-[3 was inert for inhibition of MHC class II 
in U2A cells, where all components of IFN type I signaling 
were intact except for gene expression through the ISGF3- 
ISRE pathway. Conversely, IFN-13 mediated weak inhibi- 
tion of MHC class II expression in U1A cells, where there 
remained a partial gene-regulatory response directed through 
the ISR_E. The inducible component that mediates inhibi- 
tion of MHC class II transcription remains to be identified. 
Several DNA-binding factors (YB-1, NF-X1) and a novel 
cytokine,  IK,  were  recently  described  as  inhibitors  of 
MHC class II expression or transcription  (46-48).  We did 
not  find  IFN-[?r-inducible  soluble  factors  that  blocked 
MHC class II expression in prior studies (20).  Induction of 
YB-1 or NF-X1 by IFN-[3 has not been addressed. 
IFN-~-mediated  inhibition  was  not  observed  for  the 
endogenous  MHC  class  II genes  that  were  constitutively 
expressed in  CIITA-transfected cells.  Furthermore,  when 
IFN-[5  treatment  was  introduced  12  h  after  transfection 
with MHC class II promoter-driven constructs, no inhibi- 
tion was observed (data not shown).  These  characteristics 
were similar to those we reported previously for IFN-[3 ef- 
fects on expression of the MHC class II genes. In particular, 
IFN-13 failed to inhibit  constitutive MHC  class II expres- 
sion by human monocytes (19,  49).  Further, we previously 
observed that IFN-[3 did not block MHC class II induction 
in  human  astrocytoma cells  that  were  highly  sensitive  to 
such inhibition, when added ~>6 h after IFN-~/(Ransohoff, 
R.,  and  G.T. Babcock,  unpublished  observations).  These 
observations may indicate that CIITA is not susceptible to 
the inhibitory effects of IFN-13 after its production and ac- 
tivation.  In this  context,  it is not  certain whether  CIITA 
expression by DNA-mediated gene transfer is identical in 
all  respects  to  its  induction  by  IFN-%  and  in  particular 
whether  posttranslational  modifications  occur  in  IFN-~/- 
induced  cells.  The  stoichiometric  relationship  between 
CIITA and IFN-[3-induced inhibitor(s) may also be critical 
for interpretation  of these  experiments.  It is possible that 
CIITA levels in stably transfected cells  are sufficient to ti- 
trate IFN-[5-induced components, so that inhibition of  MHC 
class II promoter expression is relatively modest (Fig. 2). 
Recent information about functional domains of CIITA 
has come from detailed structure-function analysis (34,  35). 
A  surprisingly  strong  NH2-terminal  acidic  transactivation 
domain functions efficiently for heterologous promoters and 
in yeast cells, indicating general competence as a eukaryotic 
transactivator. CIITA requires the conserved MHC class II 
DNA  elements  to  drive  transcription,  a  property  that  is 
conferred by the COOH  terminus of the protein, possibly 
through physical interaction with factors that contact DNA 
directly.  Our  finding  that  CIITA function  is  sensitive  to 
IFN-[3 action  suggests the prospect that  CIITA-mediated 
transactivation  or  interaction  with  DNA-binding  factors 
may be targeted by an  IFN-inducible  component.  These 
possibilities can be experimentally addressed. 
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